These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 12410513

  • 1. A randomized prospective trial of ioxaglate 320 (Hexabrix) vs. iodixanol 320 (Visipaque) in patients undergoing percutaneous coronary intervention.
    Sutton AG, Ashton VJ, Campbell PG, Price DJ, Hall JA, de Belder MA.
    Catheter Cardiovasc Interv; 2002 Nov; 57(3):346-52. PubMed ID: 12410513
    [Abstract] [Full Text] [Related]

  • 2. Influence of a nonionic, iso-osmolar contrast medium (iodixanol) versus an ionic, low-osmolar contrast medium (ioxaglate) on major adverse cardiac events in patients undergoing percutaneous transluminal coronary angioplasty: A multicenter, randomized, double-blind study. Visipaque in Percutaneous Transluminal Coronary Angioplasty [VIP] Trial Investigators.
    Bertrand ME, Esplugas E, Piessens J, Rasch W.
    Circulation; 2000 Jan 18; 101(2):131-6. PubMed ID: 10637198
    [Abstract] [Full Text] [Related]

  • 3. [Comparison of iodixanol (Visipaque) and ioxaglate (Hexabrix) in coronary angiography and ventriculography: a double-blind randomized study].
    Roriz R, de Gevigney G, Finet G, Nantois-Collet C, Borch KW, Amiel M, Beaune J.
    J Radiol; 1999 Jul 18; 80(7):727-32. PubMed ID: 10431273
    [Abstract] [Full Text] [Related]

  • 4. Renal toxicity evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: the RECOVER study: a randomized controlled trial.
    Jo SH, Youn TJ, Koo BK, Park JS, Kang HJ, Cho YS, Chung WY, Joo GW, Chae IH, Choi DJ, Oh BH, Lee MM, Park YB, Kim HS.
    J Am Coll Cardiol; 2006 Sep 05; 48(5):924-30. PubMed ID: 16949481
    [Abstract] [Full Text] [Related]

  • 5. Cardiac events after low osmolar ionic or isosmolar nonionic contrast media utilization in the current era of coronary angioplasty.
    Le Feuvre C, Batisse A, Collet JP, Batisse JP, Choussat R, Beygui F, Helft G, Montalescot G, Metzger JP.
    Catheter Cardiovasc Interv; 2006 Jun 05; 67(6):852-8. PubMed ID: 16649230
    [Abstract] [Full Text] [Related]

  • 6. Immediate and late adverse reactions in coronary angiography. A comparison between iodixanol and ioxaglate.
    Fransson SG, Stenport G, Andersson M.
    Acta Radiol; 1996 Mar 05; 37(2):218-22. PubMed ID: 8600966
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Ionic low-osmolar versus nonionic iso-osmolar contrast media to obviate worsening nephropathy after angioplasty in chronic renal failure patients: the ICON (Ionic versus non-ionic Contrast to Obviate worsening Nephropathy after angioplasty in chronic renal failure patients) study.
    Mehran R, Nikolsky E, Kirtane AJ, Caixeta A, Wong SC, Teirstein PS, Downey WE, Batchelor WB, Casterella PJ, Kim YH, Fahy M, Dangas GD.
    JACC Cardiovasc Interv; 2009 May 05; 2(5):415-21. PubMed ID: 19463464
    [Abstract] [Full Text] [Related]

  • 11. The assessment of thrombotic markers utilizing ionic versus non-ionic contrast during coronary angiography and intervention trial.
    Shah B, Berger JS, Allen N, Guo Y, Sedlis SP, Xu J, Perez A, Attubato M, Slater J, Feit F.
    Catheter Cardiovasc Interv; 2016 Nov 05; 88(5):727-737. PubMed ID: 26773574
    [Abstract] [Full Text] [Related]

  • 12. Visipaque (iodixanol) and hexabrix (ioxaglate) in renal insufficiency.
    Deray G.
    J Am Coll Cardiol; 2007 Apr 17; 49(15):1668. PubMed ID: 17433961
    [No Abstract] [Full Text] [Related]

  • 13. Evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in coronary angiography.
    Persson P, Liss P, Hansell P.
    J Am Coll Cardiol; 2007 Apr 17; 49(15):1668-1669. PubMed ID: 17433962
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Iodixanol in cardioangiography. A double-blind parallel comparison between iodixanol 320 mg I/ml and ioxaglate 320 mg I/ml.
    Tveit K, Bolz KD, Bolstad B, Haugland T, Berg KJ, Skjaerpe T, Kloster YF.
    Acta Radiol; 1994 Nov 17; 35(6):614-8. PubMed ID: 7946687
    [Abstract] [Full Text] [Related]

  • 17. A prospective, double-blind, randomized, controlled trial on the efficacy and cardiorenal safety of iodixanol vs. iopromide in patients with chronic kidney disease undergoing coronary angiography with or without percutaneous coronary intervention.
    Nie B, Cheng WJ, Li YF, Cao Z, Yang Q, Zhao YX, Guo YH, Zhou YJ.
    Catheter Cardiovasc Interv; 2008 Dec 01; 72(7):958-65. PubMed ID: 19021282
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Early and late reactions after the use of iopamidol 340, ioxaglate 320, and iodixanol 320 in cardiac catheterization.
    Sutton AG, Finn P, Grech ED, Hall JA, Stewart MJ, Davies A, de Belder MA.
    Am Heart J; 2001 Apr 01; 141(4):677-83. PubMed ID: 11275937
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.